Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

77.37EUR
30 Oct 2020
Change (% chg)

€-0.86 (-1.10%)
Prev Close
€78.23
Open
€76.96
Day's High
€77.91
Day's Low
€76.70
Volume
2,775,932
Avg. Vol
1,881,531
52-wk High
€95.82
52-wk Low
€67.65

Summary

Name Age Since Current Position

Serge Weinberg

69 2015 Independent Chairman of the Board

Paul Hudson

52 2019 Chief Executive Officer, Member of the Executive Committee, Director

Jean-Baptiste Chasseloup de Chatillon

54 2018 Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

61 2014 Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

60 2018 Executive Vice President of Human Resources, Member of the Executive Committee

Olivier Charmeil

57 2019 Executive Vice President - China and Emerging Markets, Member of the Executive Committee

David Loew

53 2016 Executive Vice President - Sanofi Pasteur; Member of the Executive Committee

Philippe Luscan

57 2015 Executive Vice President - Global Industrial Affairs, Member of the Executive Committee

Alan Main

57 2016 Executive Vice President - Consumer Healthcare, Member of the Executive Committee

John Reed

61 2018 Executive Vice President - Global Head of Research and Development, Member of the Executive Committee

William Sibold

53 2017 Executive Vice President - Sanofi Genzyme, Member of the Executive Committee

Laurent Attal

62 2012 Director

Christophe Babule

54 2019 Director

Bernard Charles

63 2017 Independent Director

Claudie Haignere

62 2008 Independent Director

Patrick Kron

66 2014 Independent Director

Fabienne Lecorvaisier

57 2013 Independent Director

Melanie Lee

61 2017 Independent Director

Suet-Fern Lee

61 2011 Independent Director

Carole Piwnica

62 2010 Independent Director

Gilles Schnepp

61 2020 Independent Director

Diane Souza

67 2016 Independent Director

Thomas Suedhof

64 2016 Independent Director

Arnaud Delepine

2019 Investor Relations Officer

Biographies

Name Description

Serge Weinberg

Mr. Serge Weinberg serves as Independent Chairman of the Board of the Company. He was Independent Chairman of the Board, Interim Chief Executive Officer from October 29, 2014 to April 2, 2015; Chairman of the Board from May 17, 2010 and October 29, 2014; Director from December 16, 2009 and May 17, 2010. He is Chairman of the Appointments and Governance Committee (as of October 28, 2015), and Chairman of the Strategy Committee of the Company, as well as Member of the Company's Scientific Committee. Since 2015 he has been Chairman of the investment firm Weinberg Capital Partners. Previously, he was Director of Sanofi SA from December 16, 2009 until May 17, 2010. He became Chief of Staff of the French Budget Minister, Laurent Fabius, in 1981. After a position of Deputy General Manager for Finance at the French Television Channel FR3 (1982-1983), he became Chief Executive Officer and then Chairman of the Havas Tourisme Group, the function he held from 1983 to 1987. He was then appointed CEO of Pallas Finance for three years and joined the Pinault Group in 1990 as President of CFAO. In the Pinault Group, he was then appointed Chairman and CEO of Rexel for the period from 1991 to 1995 and chaired the Management Board of the PPR Group for 10 years. In March 2005, he founded the investment firm Weinberg Capital Partners, which manages funds dedicated to LBO and real estate. Mr. Weinberg was also Non-Executive Chairman of the Board of the Accor Group from 2006 to 2009. Mr. Weinberg obtained a degree in Law from the Institut d'Etudes Politiques de Paris and obtained a degree from the ENA - Ecole Nationale d'Administration Publique in 1976.

Paul Hudson

Mr. Paul Hudson serves as Chief Executive Officer, Member of the Executive Committee, Director of the Company. He has been CEO of Novartis Pharmaceuticals unit since 2016 and is a member of Novartis' executive committee. Various operational and managerial positions at AstraZeneca (including President, AstraZeneca US; Executive Vice President, North America; and Representative Director & President, AstraZeneca KK, Japan, President of AstraZeneca Spain, and Vice-President and head of Primary Care United-Kingdom); Various operational and managerial positions at Schering-Plough, including Head of Global Marketing for biologicals.

Jean-Baptiste Chasseloup de Chatillon

Mr. Jean-Baptiste Chasseloup de Chatillon serves as Chief Financial Officer, Executive Vice President, Member of the Executive Committee of the Company. Mr. Chasseloup de Chatillon most recently served as Chief Financial Officer and Executive Vice-President for PSA Group. In this capacity he was also a member of the Managing Board and of the Executive Committee. Throughout his tenure at PSA Group, he held various management positions in finance (Treasurer in Spain, Chief Financial Officer in the United Kingdom) and in sales and marketing (Citroen Belgium Managing Director). He was also Chairman of the Board of Banque PSA Finance (BPF) from 2012 to June 2016. He has been a member of the Peugeot's Managing Board since 2012.

Karen Linehan

Ms. Karen Linehan serves as Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee of the Company. Previously, she served as Senior Vice President - Legal Affairs and General Counsel, Global Compliance Officer Interim, Member of the Executive Committee and the Global Leadership Team of the Company from 2011 to April 1, 2012. Between March 26, 2007 and 2011, she held the functions of Senior Vice President - Legal Affairs and General Counsel, Member of the Executive Committee and Management Committee of Sanofi SA. Prior to practicing law, Ms. Linehan served on the congressional staff of the Speaker of the U.S. House of Representatives from September 1977 to August 1986. Until December 1990, she was Associate in a law firm in New York, New York. In January 1991, she joined Sanofi as Assistant General Counsel of its US subsidiary. In July 1996, Ms. Linehan moved to Paris to work on international matters within the Group and she has held a number of positions within the Legal Department, most recently as Vice President - Deputy Head of Legal Operations. Ms. Linehan graduated from Georgetown University with a Bachelor of Arts degree in Literature and a Juris Doctor degree in Law.

Caroline Luscombe

Ms. Caroline Luscombe serves as Executive Vice President of Human Resources, Member of the Executive Committee of the Company. She holds bachelor's degree in German from University College London. She began her accounting career at Arthur Young McClelland Moore and also practiced functions of Controller and Director of Compensation and Social Protection at Bain & Company in the UK. She was until recently Head of Organization and Human Resources and member of the Executive Committee of LafargeHolcim. Before joining LafargeHolcim, she served as Human Resources Manager and was a member of the Executive Committee at Syngenta. She also held several senior positions in the field of human resources at General Electric (GE), including Director of Resources Human Resources of GE Capital Global Banking, GE Money and GE Healthcare Bio-Sciences. She was also Executive Vice President of Human Resources of the Medical Diagnostics Division of Amersham plc., before its acquisition by GE.

Olivier Charmeil

Mr. Olivier Charmeil serves as Executive Vice President - China and Emerging Markets, Member of the Executive Committee of the Company. He previously served as Executive VP of General Medicines & Emerging Markets; Member of the Executive Committee since June 2016. Prior to that, he was Executive Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team of the Company. He joined the Company as Senior Vice President - Pharmaceutical Operations in Asia-Pacific Region on February 1, 2006, the function he held until January 1, 2008, when he became appointed Senior Vice President - Pharmaceutical Operations in Asia Pacific Region and Japan for over one year, until February 2009. From then to January 1, 2011, he served as Senior Vice President - Asia/Pacific & Japan Vaccines, Member of the Management Committee of the Company. From 1989 to 1994, he worked in the Mergers and Acquisitions department of Banque de l’Union Europeenne. He joined Sanofi Pharma in 1994 as Head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Synthelabo in 1999 and Attache to the Chairman, Jean-Francois Dehecq, in 2000, before being appointed as Vice President of Development within the Sanofi-Synthelabo International Operations Division, where he was responsible for China and support functions. In 2003, Mr. Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthelabo France, before taking the post of Senior Vice President of Business Management and Support within the Pharmaceutical Operations Division. Mr. Charmeil obtained a degree from the Hautes etudes commerciales (HEC) and from the Institut d'Etudes Politiques de Paris.

David Loew

Mr. David Loew serves as Executive Vice President - Sanofi Pasteur; Member of the Executive Committee of the Company. He has a degree in Finance and Marketing and an MBA, both from Universitaet St. Gallen. He started his career in the United States at Coopers & Lybrand and Hewlett Packard in 1990, before joining Roche in 1992. Over the next 21 years, he held a variety of positions with Roche including Global Oncology Head, General Manager Switzerland, Global Chief Marketing Officer & Head of Global Product Strategy, Region Head Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President Commercial Operations Europe and became Head Global Commercial Operations Sanofi Pasteur in January 2016.

Philippe Luscan

Mr. Philippe Luscan serves as Executive Vice President - Global Industrial Affairs, Member of the Executive Committee of the Company. Prior to that, he was Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team and Vice President - Chemistry at the Company. He graduated from Ecole Polytechnique and from Ecole des Mines de Paris in Biotechnology. He started his career with Danone in 1987 as Head of Production. In 1990, he joined the Company as Head of site at Sanofi Chemistry in Sisteron and was then named Head of industrial affairs at Sanofi in the United States followed by an appointment as Vice President Supply Chain, before being named Vice President Chemistry in September 2006.

Alan Main

Dr. Alan Main Ph.D. serves as Executive Vice President - Consumer Healthcare, Member of the Executive Committee of the Company. Alan Main has his BA (Hons) in International Marketing from Thames Polytechnic of Thames College London, and has completed various executive and leadership development programs at London, Harvard and Columbia Business Schools, as well as INSEAD (Asia). Originally from Scotland, Alan has lived and worked in the United States, Europe, Hong Kong and South Africa. Alan has more than 30 years of marketing and general management experience in the Consumer Health and Medical Device fields. Alan began his career with Stafford Miller/Block Drug (now part of GlaxoSmithKline), before joining Merrell Dow (now Sanofi) in the UK, then London Rubber Company (now SSL). In 1992 Alan joined Roche Consumer Health and spent five years as a marketing manager in the UK, before transferring to South Africa for his first country General Manager role. In 2002 Alan was promoted to head of Asia Pacific for Roche Consumer Health. In 2004 Alan’s responsibilities expanded to include Russia, Turkey, Middle East, and African territories. Following Bayer’s acquisition of the Roche Consumer Health in 2004, Alan continued to hold key operational roles, including Region Head for Asia Pacific and Europe. In 2010 Alan transferred to the medical device business of Bayer as Global President for Bayer Medical Care. Alan was also the Chairman of the Bayer Healthcare Marketing Excellence Council. He holds a Bachelor of Science degree from University of Aberdeen, and a PhD in Organic Chemistry from University of Liverpool.

John Reed

Prof. Dr. John C. Reed M.D. Ph.D. serves as Executive Vice President - Global Head of Research and Development, Member of the Executive Committee of the Company. serves as Executive Vice President - Global Head of Research and Development, Member of the Executive Committee of the Company. He began his academic career at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at Hospital of University Pennsylvania. He then joined the Burnham Institute in 1992, one of the best known biomedical research institutes in the U.S, where he held multiple positions of increasing responsibility such as Program Director of the NCI-designated Cancer Center, Scientific Director, and Director of the Cancer Center. In 2002 he was appointed President and CEO of the Sanford-Burnham Medical Research Institute. From 2013 to 2018, Dr. Reed has served as the Global Head of Roche Pharma Research & Early Development (pRED), responsible for directing research and early development activities through Phase 2b proof-of-concept (PoC) across all therapeutic areas, including oncology, immunology, rare diseases, neuroscience, ophthalmology and infectious diseases. He was also a member of Roche’s Corporate Executive Committee, reporting to the CEO. Prof.Dr. Reed holds a B.A in chemistry from the University of Virginia, Charlottesville and a M.D. PhD. from the University of Pennsylvania, School of Medicine.

William Sibold

Mr. William J. Sibold serves as Executive Vice President - Sanofi Genzyme, Member of the Executive Committee of the Company. Bill Sibold holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University. He has more than twenty-five years of experience in the biopharmaceutical industry since starting his career with Eli Lilly. He held a number of leadership positions within Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology and general management of Biogen’s Australian and Asia-Pacific business. In addition to his time with Biogen, Mr. Sibold also served as the chief commercial officer of Avanir Pharmaceuticals. Bill Sibold joined Sanofi in late 2011 as head of the M S franchise where he oversaw the successful launches of Aubagio and Lemtrada. He most recently served as head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, a position he held as of January 2016 until June 2017 and where he led preparation for the global launches of Dupilumab and Sarilumab.

Laurent Attal

Mr. Laurent Attal serves as Director of the Company. He is also Member of the Strategy Committee and Member of the Scientific Committee of the Company. Since January 2010, he is Executive Vice President Research & Innovation of l’Oreal. Additionally, he is Director of Fondation d’Entreprise L’Oreal (France). Mr. Attal joined L'Oreal in 1986 in France as Sales Representative. Over the next several years, he held various positions within the Active Cosmetics division and was appointed CEO of Vichy in 1994. Four years later, Mr. Attal was named President of the Active Cosmetics division, with brands including Vichy, La Roche-Posay and Inneov, L'Oreal / Nestle joint venture of Nutricosmetics. In 2002, Mr. Attal became Member of the Executive Committee of L'Oreal and also oversaw the activities of the pharmaceutical company Galderma, the joint-venture between Nestle and L'Oreal. In 2005, he was appointed President and CEO of L'Oreal USA. He obtained a Doctorate of Medicine in Dermatology from the Faculty of Medicine in Paris (Faculte de Medecine de Paris), and holds a Masters of Business Administration degree from the INSEAD.

Christophe Babule

Mr. Christophe Babule serves as Director of the Company. Christophe Babule has been appointed Executive Vice-President, Chief Financial Officer and member of L'Oréal's Executive Committee as of mid-February 2019. Christophe Babule has spent his career with L'Oréal, which he joined in 1988 after his studies at HEC Paris. He spent 7 years in the Luxury Division in Italy before being appointed as Director of Administration & Finance based in China. In 2007, he was appointed Administration & Financial Director for Mexico. In 2010, he returned to France to join Christian Mulliez's Executive Committee as Director of Internal Audit for nearly 5 years. Afterwards he was appointed to his current position as Administration & Financial Director for the Asia Pacific Zone based in Shanghai and then in Hong Kong.

Bernard Charles

Mr. Bernard Charles serves as Independent Director of the Company. Since 1995 he has been Chief Executive Officer of Dassault Systemes and since May 2016 has has occupied the post of its Vice-Chairman of the Board of Directors. He joined the company in 1983 and created the New Technology, Research and Strategy division, before being appointed Director for Strategy, Research and Development in 1988. Through his contributions to digital mock-up, product lifecycle management and 3DEXPERIENCE. Bernard Charles helped instill a culture of ongoing innovation to further consolidate Dassault Systemes’ scientific capabilities and make science part of the company’s identity. Bernard Charles is a member of the Academy of Technology (France) and of the National Academy of Engineering (United States). He is a graduate of Ecole Normale Superieure de Cachan engineering school in Cachan and has a Ph.D. in mechanical engineering majoring in automation engineering and information science. He also holds an Aggregation in mechanical engineering; this is the most senior teaching qualification achievable in France. He currently acts as Chairman of the Board of Directors of Dassault Systemes Corp., Dassault Systemes SolidWorks Corp., and Dassault Systemes Simulia Corp., among others.

Claudie Haignere

Ms. Claudie Haignere serves as Independent Director of the Company. She is also Member of the Appointments and Governance Committee, and Member of the Compensation Committee of the Company. She began her career as a rheumatologist at Cochin Hospital in Paris in 1984. In 1996, she participated in the scientific space mission to the MIR space station (Cassiopee, Franco-Russian mission), then in 2001, in the scientific and technical space mission to the International Space Station (Andromede mission). From 2002 to 2004, she was Deputy Minister for Research and New Technologies in the French government, then Deputy Minister for European Affairs from 2004 to 2005. Between 2005 and 2009, she was Counselor to the European Space Agency (ESA). Ms. Haignere is currently Director for several companies and foundations in France including: Intitut IRIS, Fondation CGenial and Fondation d’Entreprise L’Oreal, among others. She is also Member of Academie des Technologies, of Academie des Sports, of Academie Nationale de l’Air et de l’Espace. She served as Chairman of the Board of Directors of La Geode and Chairman of Universcience (Cite des Sciences et de l’Industrie and Palais de la Decouverte).

Patrick Kron

Mr. Patrick Kron serves as Independent Director of the Company. He is Chairman of the Compensation Committee (as of 2016), Member of the Appointments and Governance Committee (as of May 4, 2015), and Member of the Strategy Committee of the Company. Since November 2016, he has been President of Truffle Capital. He is a graduate of Ecole Polytechnique and Ecole des Mines de Paris (Engineering). He started his career in the French Ministry of Industry where he served from 1979 until 1984. He then joined the Pechiney Group where from 1984 until 1988 he held operational responsibilities in one of the Group’s most important factories in Greece, becoming manager of the Greek subsidiary. From 1988 to 1993, he occupied several senior operational and financial positions within Pechiney, first managing a group of activities in the processing of aluminum and eventually as President of the Electrometallurgy Division. In 1993, he became a member of the Executive Committee of the Pechiney Group and was appointed Chairman of the Board of the Carbone Lorraine Company, a position he held until 1997. From 1995 to 1997, he ran the Food and Health Care Packaging Sector of Pechiney and held the position of Chief Operating Officer of the American National Can Company in Chicago (USA). From 1998 to 2002, Mr. Kron was Chief Executive Officer of Imerys before joining Alstom in 2002. He was Chief Executive Officer of Alstom from January 1, 2003, and Chairman and Chief Executive Officer as of March 11, 2003 until 2016. Mr. Kron was awarded the Legion d’honneur in 2004 and is Officer of National Order of Merit since 2007.

Fabienne Lecorvaisier

Ms. Fabienne Lecorvaisier serves as Independent Director of the Company. She was Member of the Audit Committee of the Company, and has been appointed its Chairman as of May 2, 2018. She is a graduate of Ecole Nationale des Ponts et Chaussees. Since July 2017 she has been Member of the Executive Committee and Deputy CEO in charge of Finance at Air Liquide. She began her career at Societe Generale and later held various positions at Barclays Bank and the Banque du Louvre. In 1993, she joined the Essilor Group as Development Director before being appointed Finance and Information Systems Director of Essilor America in 1996, then Chief Financial Officer of the Group in 2001 and Senior Vice-President Strategy and Acquisitions in 2007. In 2008, she was appointed Vice-President, Finance and Administration of the Air Liquide Group, and member of its Group Executive Committee. Ms. Lecorvaisier is currently also Chief Executive Officer and Chairwoman of Air Liquide Finance.

Melanie Lee

Dr. Melanie Lee serves as Independent Director of the Company. Most recently, she was Chief Scientific Officer at BTG plc (2014 -2018), a company which operates in interventional medicine in vascular disease, oncology and pulmonology. She is currently Director of Think10 (United Kingdom) as well as CEO of LifeArc (since 2018). Following her academic career she spent 10 years at Glaxo/GlaxoWellcome (1988-1998). In 1998, Melanie joined Celltech plc as Executive Director of Research. Celltech plc was subsequently acquired by UCB where she became Executive Vice President, Research and Development. After leaving UCB in 2009 she had a successful tenure as CEO at Syntaxin Ltd, a UK based biotech and following the sale to Ipsen, founded NightstaRx Ltd, a Syncona backed company in 2014. Melanie received an undergraduate degree in Biology from the University of York (2004) and then a Ph.D. at National Institute for Medical Research in London. She worked as a molecular genetics postdoc, first at Imperial College London on yeast and then from 1985 with Sir Paul Nurse, a Nobel Prize winner, at the Imperial Cancer Research Fund’s Lincoln’s Inn Laboratories. Melanie received her CBE for services to medical science in 2009.

Suet-Fern Lee

Ms. Suet-Fern Lee serves as Independent Director of the Company. She holds a law degree from Cambridge University (1980). She qualified as a Barrister-at-Law at Gray’s Inn, London in 1981 before being admitted to the Singapore Bar in 1992. She is Senior Partner at Morgan Lewis Stamford LLC and Chairwoman of the International Leadership Team of Morgan Lewis & Bockius LLP. She is a founder of Stamford Law Corporation (Singapore), where she has been a Senior Partner since 2000. Since 2006, she is a member of the Board of Trustees of Nanyang Technological University and of the Accounting Advisory Board of National University of Singapore Business School. In 2007, she became a member of the Advisory Committee of the Singapore Management University School of Law. In Singapore, she served as Director of the National Heritage Board and Rickmers Trust Management Pte Ltd. She was also Chairman of the Board of the Asian Civilizations Museum and Director of Macquarie International Infrastructure Fund Ltd (Bermuda). Currently she is also Director at Stamford Coporate Services Pte Ltd and at Morgan Lewis Stamford LLC.

Carole Piwnica

Ms. Carole Piwnica serves as Independent Director of the Company. She is founder and director of Naxos UK Ltd. since 2006 and holds various directorships in Naxos Portfolio companies in the US and the UK. Since 2010 she has served as an independent Director of Eutelsat Communications and is chairing the Board's committee for Governance, Remuneration and Selection. She is also Independent Member of the Supervisory Board of Rothschild & Co. She holds a degree in law from Universite Libre de Bruxelles and a Masters in law from New York University. She is Member of the bar of New York and Paris, and started her career in 1985 at Proskauer Rose, New York, before joining the merger & acquisitions department of Shearman & Sterling, Paris, in 1987. She was General Counsel at Gardini et Associes from 1991 to 1994 when she joined Amylum Group where she was Chairman from 1996 to 2000. Between 1996 and 2006, she was Vice-president and Board Member of Tate & Lyle Plc.

Gilles Schnepp

Mr. Gilles Schnepp serves as Independent Director of the Company. A graduate of HEC in 1981, Gilles Schnepp began his career at Merrill Lynch in 1983 before joining Legrand in 1989 where he held several positions before becoming Deputy Chief Executive Officer in 2001, Chief Executive Officer in 2004 and Chairman and Chief Executive Officer in 2006. Since 2018, he has been Chairman of the Board of Directors. Gilles Schnepp has also been a member of the Board of Directors of Saint Gobain since 2009 and Vice-Chairman of the Supervisory Board of PSA since 2019. Gilles Schnepp thus brings to the Board his skills in financial matters and his experience in managing international groups.

Diane Souza

Ms. Diane Souza serves as Independent Director of the Company. She is Member of the Audit and Compensation Committees of the Company. She is the former CEO of United Healthcare Specialty Benefits. She is a member of the Board of Directors of Farm Credit East in the United States. She began her career with Price Waterhouse in 1979 as Audit Staff Accountant before assuming several senior positions at Deloitte Haskins & Sells, from Audit Staff Accountant to Senior Tax Manager-in-Charge, from 1980 to 1988. She returned to Price Waterhouse from 1988 to 1994, where she notably held the position of Head of the Northeast Insurance Tax Region. In 1994 Diane Souza joined Aetna and UnitedHealtcare in 2008. Former CEO of UnitedHealthcare Specialty Benefits, Diane Souza has over 25 years of managed care and health benefits experience, she led healthcare operations and business and large-scale systems transformation at UnitedHealthcare and Aetna, as well as delivery of the integrated market strategy for the Affordable Care Act. She also served as CFO of Aetna’s Guaranteed Products business, where she was regularly involved in complex financial transactions. Ms. Diane Souza is a Certified Public Accountant, holds a degree in Accounting from University of Massachusetts, an honorary doctorate in Business studies from University of Massachusetts Dartmouth and a diploma in dental hygiene from Northeastern University, Forsyth School for Dental Hygienists.

Thomas Suedhof

Dr. Thomas Suedhof serves as Independent Director of the Company. He is Chairman of the Scientific Committee of the Company. He holds a Medical Degree from the Georg-August-Universitaet Goettingen (Germany) and a Medical Degree from Aachen University (Germany). He is the Avram Goldstein Professor in the School of Medicine of Stanford University, as well as a Professor of Molecular & Cellular Physiology, Psychiatry, and Neurology. Prior to this position, he spent 25 years at the University of Texas, Southwestern, where he acted as Chairman of the Department of Neuroscience. Most of his research at that time focused on the mechanisms of synaptic information transmission which have pharmacological consequences for the treatment of neurodegenerative and neuro-psychiatric diseases. He won the Nobel Prize in Physiology or Medicine (shared with James Rothman and Randy Shekman) in 2013, the Albert Lasker Medical Basic Research Award together with Richard Scheller, as well as the Bernhard Katz Award of the Biophysical Society (shared with Reinhard Jahn).

Arnaud Delepine